Table 1. Demographic, clinical, and treatment-related characteristics of patients diagnosed with prostate cancer and treated between 2002 and 2010 in the Brazilian Public Health System (SUS), Brazil.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL</td>
<td>112,856</td>
<td>100</td>
</tr>
<tr>
<td><strong>Age in years</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>70.5 (9.0)</td>
<td>-</td>
</tr>
<tr>
<td>Median</td>
<td>71.0</td>
<td>-</td>
</tr>
<tr>
<td><strong>Age group at the start of the follow-up (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19 - 59</td>
<td>12,717</td>
<td>11.3</td>
</tr>
<tr>
<td>60 - 69</td>
<td>35,927</td>
<td>31.8</td>
</tr>
<tr>
<td>70 - 79</td>
<td>47,870</td>
<td>42.5</td>
</tr>
<tr>
<td>≥ 80</td>
<td>16,342</td>
<td>14.4</td>
</tr>
<tr>
<td><strong>Year of treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>7,894</td>
<td>7.0</td>
</tr>
<tr>
<td>2003</td>
<td>8,885</td>
<td>7.9</td>
</tr>
<tr>
<td>2004</td>
<td>11,019</td>
<td>9.8</td>
</tr>
<tr>
<td>2005</td>
<td>8,964</td>
<td>7.8</td>
</tr>
<tr>
<td>2006</td>
<td>10,889</td>
<td>9.7</td>
</tr>
<tr>
<td>Year</td>
<td>Number</td>
<td>Cancer Incidence Rate</td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>2007</td>
<td>12,541</td>
<td>11.1</td>
</tr>
<tr>
<td>2008</td>
<td>17,408</td>
<td>15.4</td>
</tr>
<tr>
<td>2009</td>
<td>16,889</td>
<td>15.0</td>
</tr>
<tr>
<td>2010</td>
<td>18,367</td>
<td>16.3</td>
</tr>
</tbody>
</table>

**Region of residence**

<table>
<thead>
<tr>
<th>Region</th>
<th>Number</th>
<th>Cancer Incidence Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Southeast</td>
<td>59,979</td>
<td>53.2</td>
</tr>
<tr>
<td>South</td>
<td>18,986</td>
<td>16.8</td>
</tr>
<tr>
<td>Midwest</td>
<td>6,555</td>
<td>5.8</td>
</tr>
<tr>
<td>North</td>
<td>3,849</td>
<td>3.4</td>
</tr>
<tr>
<td>Northeast</td>
<td>23,487</td>
<td>20.8</td>
</tr>
</tbody>
</table>

**Cancer stages**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Number</th>
<th>Cancer Incidence Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>9,482</td>
<td>8.4</td>
</tr>
<tr>
<td>Stage II</td>
<td>39,758</td>
<td>35.2</td>
</tr>
<tr>
<td>Stage III</td>
<td>30,962</td>
<td>27.4</td>
</tr>
<tr>
<td>Stage IV</td>
<td>32,654</td>
<td>29.0</td>
</tr>
</tbody>
</table>

**First treatment**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number</th>
<th>Cancer Incidence Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy</td>
<td>24,899</td>
<td>22.1</td>
</tr>
<tr>
<td>Systemic treatment</td>
<td>36,818</td>
<td>32.6</td>
</tr>
<tr>
<td>Radiotherapy + systemic treatment</td>
<td>28,961</td>
<td>25.7</td>
</tr>
<tr>
<td>Combined surgery</td>
<td>22,178</td>
<td>19.6</td>
</tr>
<tr>
<td>------------------</td>
<td>--------</td>
<td>------</td>
</tr>
</tbody>
</table>

**Number of Elixhauser’s comorbidity**

| 0 | 13,757 | 12.2 |
| 1 to 3 | 48,321 | 42.8 |
| ≥ 4 | 50,778 | 45.0 |

**Hospital admissions**

| No | 41,352 | 36.6 |
| Yes | 71,504 | 63.4 |

**Number of hospital admissions**

| 0 | 41,352 | 36.6 |
| 1 | 24,549 | 21.7 |
| 2 | 16,099 | 14.3 |
| 3 | 10,615 | 9.4 |
| 4 | 6,931 | 6.2 |
| ≥ 5 | 13,310 | 11.8 |

**Death during the study period**

| No | 62,307 | 55.2 |
| Yes, due to prostate cancer | 23,167 | 20.5 |
| Yes, due to other causes | 27,382 | 24.3 |
| Follow-up time (months) | Mean ± SD | 70.7 (40.3) | - |

SD: standard deviation.

Source: Base Onco, 2015
Table 2. Survival probability (SP) at 60, 120, and 160 months of patients diagnosed with prostate cancer and treated between 2002 and 2010 in the Brazilian Public Health System (SUS), Brazil***.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Survival Probability (SP)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Prostate cancer</td>
</tr>
<tr>
<td>Time (months)</td>
<td>60</td>
</tr>
<tr>
<td>Total</td>
<td>0.83</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
</tr>
<tr>
<td>19 - 59</td>
<td>0.85</td>
</tr>
<tr>
<td>60 - 69</td>
<td>0.85</td>
</tr>
<tr>
<td>70 - 79</td>
<td>0.84</td>
</tr>
<tr>
<td>≥ 80</td>
<td>0.76</td>
</tr>
<tr>
<td>Region of residence</td>
<td></td>
</tr>
<tr>
<td>Southeast</td>
<td>0.85</td>
</tr>
<tr>
<td>South</td>
<td>0.80</td>
</tr>
<tr>
<td>Midwest</td>
<td>0.82</td>
</tr>
<tr>
<td>North</td>
<td>0.84</td>
</tr>
<tr>
<td>Northeast</td>
<td>0.83</td>
</tr>
<tr>
<td>Clinical stages</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td>0.92</td>
</tr>
<tr>
<td>--------</td>
<td>------</td>
</tr>
<tr>
<td>Stage II</td>
<td>0.91</td>
</tr>
<tr>
<td>Stage III</td>
<td>0.86</td>
</tr>
<tr>
<td>Stage IV</td>
<td>0.69</td>
</tr>
</tbody>
</table>

**First treatment**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>0.94</th>
<th>0.91</th>
<th>0.90</th>
<th>0.83</th>
<th>0.68</th>
<th>0.60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy</td>
<td>0.79</td>
<td>0.73</td>
<td>0.71</td>
<td>0.79</td>
<td>0.69</td>
<td>0.65</td>
</tr>
<tr>
<td>Systemic treatment</td>
<td>0.85</td>
<td>0.77</td>
<td>0.74</td>
<td>0.86</td>
<td>0.75</td>
<td>0.69</td>
</tr>
<tr>
<td>Radiotherapy + Systemic treatment</td>
<td>0.78</td>
<td>0.69</td>
<td>0.66</td>
<td>0.86</td>
<td>0.75</td>
<td>0.70</td>
</tr>
</tbody>
</table>

**Number of Elixhauser comorbidity**

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>0.95</th>
<th>0.94</th>
<th>0.92</th>
<th>0.99</th>
<th>0.98</th>
<th>0.99</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.83</td>
<td>0.79</td>
<td>0.77</td>
<td>0.88</td>
<td>0.81</td>
<td>0.76</td>
</tr>
<tr>
<td>1-3</td>
<td>0.79</td>
<td>0.71</td>
<td>0.69</td>
<td>0.74</td>
<td>0.56</td>
<td>0.49</td>
</tr>
<tr>
<td>≥ 4</td>
<td>0.89</td>
<td>0.85</td>
<td>0.83</td>
<td>0.88</td>
<td>0.80</td>
<td>0.76</td>
</tr>
</tbody>
</table>

**Number of hospital admissions**

<table>
<thead>
<tr>
<th>Admissions</th>
<th>0.89</th>
<th>0.85</th>
<th>0.83</th>
<th>0.88</th>
<th>0.80</th>
<th>0.76</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.85</td>
<td>0.80</td>
<td>0.78</td>
<td>0.84</td>
<td>0.74</td>
<td>0.69</td>
</tr>
<tr>
<td>1</td>
<td>0.81</td>
<td>0.74</td>
<td>0.72</td>
<td>0.81</td>
<td>0.69</td>
<td>0.63</td>
</tr>
<tr>
<td></td>
<td>0.77</td>
<td>0.69</td>
<td>0.67</td>
<td>0.78</td>
<td>0.66</td>
<td>0.60</td>
</tr>
<tr>
<td>-----</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>3</td>
<td>0.76</td>
<td>0.67</td>
<td>0.64</td>
<td>0.77</td>
<td>0.62</td>
<td>0.56</td>
</tr>
<tr>
<td>≥5</td>
<td>0.75</td>
<td>0.65</td>
<td>0.62</td>
<td>0.76</td>
<td>0.58</td>
<td>0.51</td>
</tr>
</tbody>
</table>

*Note: Estimated mean time in relation to 163 months of follow-up; **no 95%CI and SD have been added to the model.

Source: Base Onco, 2015
Table 3. Pearson correlation between time and standardized Schoenfeld residuals for deaths from prostate cancer and death from other causes.

<table>
<thead>
<tr>
<th>VARIABLES</th>
<th>DEATH PROSTATE CANCER</th>
<th>DEATH OUTHER CAUSES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rho*</td>
<td>p</td>
</tr>
<tr>
<td>Age in years</td>
<td>-0.01</td>
<td>0.1178</td>
</tr>
<tr>
<td>Region of residence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>0.02</td>
<td>0.0078</td>
</tr>
<tr>
<td>Midwest</td>
<td>0.02</td>
<td>0.0004</td>
</tr>
<tr>
<td>North</td>
<td>0.01</td>
<td>0.0477</td>
</tr>
<tr>
<td>Northeast</td>
<td>0.01</td>
<td>0.1667</td>
</tr>
<tr>
<td>Clinical stages</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td>0.01</td>
<td>0.0575</td>
</tr>
<tr>
<td>Stage III</td>
<td>-0.01</td>
<td>0.0961</td>
</tr>
<tr>
<td>Stage IV</td>
<td>-0.09</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>First treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic treatment</td>
<td>0.08</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Radiotherapy + systemic</td>
<td>0.14</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>Combined surgery</td>
<td>0.16</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Number of Elixhauser comorbidity</td>
<td>0.05</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Number of hospital admissions</td>
<td>0.00</td>
<td>0.6537</td>
</tr>
<tr>
<td>GENERAL</td>
<td>–</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

Note: * Linear correlation coefficient

Source: Base Onco, 2015